文献速递浆细胞疾病造血干细胞移植与细胞治疗

BCMA导向的嵌合抗原受体T细胞疗法治疗浆细胞白血病的安全性与疗效

Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.
PubMed 文献 · Blood Adv · 2025-01-01

这项多中心回顾性分析纳入34例接受ide-cel或cilta-cel治疗的浆细胞白血病患者,中位随访11.9个月时,总体中位无进展生存期为9.0个月(95%CI 4-15),中位总生存期为13.0个月(95%CI 8至不可估计)。接受cilta-cel治疗的患者中位无进展生存期(19.0个月 vs 6.0个月)和中位总生存期(>23个月[不可估计] vs 9.0个月)均长于接受ide-cel治疗的患者。

要点

  • 34例浆细胞白血病患者接受BCMA CAR-T治疗,总体中位无进展生存期9.0个月,中位总生存期13.0个月。
  • cilta-cel组中位无进展生存期19.0个月 vs ide-cel组6.0个月,中位总生存期>23个月 vs 9.0个月。
  • 血液学和非血液学毒性发生率两组相似,与多发性骨髓瘤患者中报告的一致。

核心结论

  • 在这项首个评估浆细胞白血病患者接受标准治疗CAR-T产品的多中心研究中,CAR-T安全、可行,且与历史标准相比结局改善。

研究设计与样本

  • 多中心回顾性分析,纳入34例接受BCMA导向CAR-T产品idecabtagene vicleucel(ide-cel)或ciltacabtagene autoleucel(cilta-cel)治疗的浆细胞白血病患者,其中19例接受ide-cel,15例接受cilta-cel。

主要发现

  • 中位随访11.9个月,总体中位无进展生存期为9.0个月(95%CI 4-15),中位总生存期为13.0个月(95%CI 8至不可估计[NE])。
  • 1年累积进展或死亡发生率为72%,1年累积死亡发生率为47%。
  • cilta-cel组中位无进展生存期为19.0个月 vs ide-cel组6.0个月,中位总生存期为>23个月(不可估计)vs 9.0个月。
  • cilta-cel组1年累积疾病进展或死亡发生率为37.5%(95%CI 17.4-68.5),而所有接受ide-cel治疗的患者在输注后12个月内进展或死亡。
  • cilta-cel组与ide-cel组的血液学和非血液学毒性发生率相似,与多发性骨髓瘤患者中报告的一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite significant therapeutic advances in multiple myeloma (MM), outcomes in patients with plasma cell leukemia (PCL) remain dismal. We conducted a multicenter retrospective analysis of patients with PCL who were treated with the B-cell maturation antigen-directed chimeric antigen receptor T-cell (CAR-T) products idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). We identified 34 patients; 19 patients received ide-cel and 15 received cilta-cel. With a median follow-up of 11.9 months, the overall median progression-free survival (mPFS) was 9.0 months (95% confidence interval [CI], 4-15) and the median overall survival (mOS) was 13.0 months (95% CI, 8 to not estimable [NE]). The 1-year cumulative incidence of progression or death was 72%, and the 1-year cumulative incidence of death was 47%. Patients who received cilta-cel had a longer mPFS (19.0 months vs 6.0 months) and mOS (>23 months [NE] vs 9.0 months) when compared with those treated with ide-cel. Similarly, the 1-year cumulative incidence of disease progression or death was 37.5% (95% CI, 17.4-68.5) with cilta-cel, whereas all patients treated with ide-cel progressed or died within 12 months of infusion. The rates of hematologic and nonhematologic toxicities were similar between patients treated with cilta-cel and those treated with ide-cel and were consistent with those reported in patients with MM. In this first multicenter study that evaluated patients with PCL who were treated with standard-of-care CAR-T products, we show that CAR-T is safe, feasible, and associated with improved outcomes when compared with historic standards.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Galarza Fortuna GM, Peres L, Nazarenko E, et al. Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia. Blood Adv. 2025. PMID: 40875887. doi:10.1182/bloodadvances.2025016966

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。